Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors

[1]  J. Collet,et al.  Surrogate endpoints: A basis for a rational approach , 2006, European Journal of Clinical Pharmacology.

[2]  Vance W Berger,et al.  Does the Prentice criterion validate surrogate endpoints? , 2004, Statistics in medicine.

[3]  Michiel L. Bots,et al.  Intima Media Thickness as a Surrogate Marker for Generalised Atherosclerosis , 2002, Cardiovascular Drugs and Therapy.

[4]  M. Espeland,et al.  Site-specific progression of carotid artery intimal-medial thickness. , 2003, Atherosclerosis.

[5]  J. Kastelein,et al.  Surrogate markers of atherosclerosis: impact of statins. , 2003, Atherosclerosis. Supplements.

[6]  Theo Stijnen,et al.  Advanced methods in meta‐analysis: multivariate approach and meta‐regression , 2002, Statistics in medicine.

[7]  S. Kashiwagi,et al.  Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). , 2002, Journal of the American College of Cardiology.

[8]  L. Kuller.  Epidemiology and Prevention of Cardiovascular Diseases: A Global Challenge , 2002 .

[9]  A. Hofman,et al.  Is Carotid Intima-Media Thickness Useful in Cardiovascular Disease Risk Assessment?: The Rotterdam Study , 2001, Stroke.

[10]  G. Berglund,et al.  Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the &bgr;-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS) , 2001, Circulation.

[11]  A. Folsom,et al.  Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. , 2000, American journal of epidemiology.

[12]  Eary,et al.  CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS , 2000 .

[13]  S. Kiechl,et al.  The natural course of atherosclerosis. Part II: vascular remodeling. Bruneck Study Group. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[14]  S. Kiechl,et al.  The natural course of atherosclerosis. Part I: incidence and progression. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[15]  A. Zwinderman,et al.  B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). , 1998, Journal of the American College of Cardiology.

[16]  R H Selzer,et al.  The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events , 1998, Annals of Internal Medicine.

[17]  Surrogate markers , 1998 .

[18]  A. Folsom,et al.  Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. , 1997, American journal of epidemiology.

[19]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[20]  G. Gallus,et al.  Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. , 1996, The American journal of medicine.

[21]  Thomas R. Fleming,et al.  Surrogate Endpoints in Clinical Trials , 1996 .

[22]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[23]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[24]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[25]  H. Hodis,et al.  George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  H. Hodis,et al.  Arterial imaging and atherosclerosis reversal , 1994 .

[27]  W. Mack,et al.  Beneficial Effects of Colestipol‐Niacin Therapy on the Common Carotid Artery. Two‐ and Four‐Year Reduction of Intima‐Media Thickness Measured by Ultrasound , 1993, Circulation.

[28]  V. Fuster,et al.  Coronary atherosclerosis : a multifactorial disease , 1993 .

[29]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[30]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[31]  J. Wittes,et al.  Surrogate endpoints in clinical trials: cardiovascular diseases. , 1989, Statistics in medicine.

[32]  P Pignoli,et al.  Ultrasonographic measurement of the common carotid artery wall thickness in hypercholesterolemic patients. A new model for the quantitation and follow-up of preclinical atherosclerosis in living human subjects. , 1988, Atherosclerosis.

[33]  P Pignoli,et al.  Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.